Trial of DB289 for the Treatment of Stage I African Trypanosomiasis

African trypanosomiasis

Assessment of Recombinant HAT-RDT Specificity Prospective Evaluation of the Specificity of Serological Tests for Human African Trypanosomiasis Pharmacokinetic, Efficacy, Safety and Tolerability Study of a Single Dose of Acoziborole in g-HAT Paediatric Patients Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage Prospective Study on Efficacy and Safety of Acoziborole (SCYX-7158) in Patients Infected by Human African Trypanosomiasis Due to T.b. Gambiense Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the Fexinidazole Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination Monitoring Prospective Evaluation of an RDT to Screen for Gambiense HAT and Diagnose P. Falciparum Malaria Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2 Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP2 Passive Case Detection Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: Early Test-of-cure Trial of DB289 for the Treatment of Stage I African Trypanosomiasis Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase